GLP-1 Drugs May Help You Shed Weight ... And Possibly Hair
As many as 15 million American adults may be on, or have been on, GLP-1 drugs within the last year, according to wide-ranging estimates of just how much this class of medications has penetrated U.S. society within the course of only a few years. Even more people have at least given this style of drug a try–KFF polling found that more than 18% of U.S. adults reported that they had at least tried GLP-1s, which have only been approved for weight loss since 2021. Although initially developed specifically for diabetes treatment, it’s fair to say that they’ve already begun to remake American bodies on a societal level, leading to the obesity rate beginning to drop for the first time in decades. Like most any class of medication, however, there tend to be side effects, and a new study in the journal Science Progress highlights one that might not initially be an obvious risk of taking GLP-1s: Hair loss.
The study found that semaglutide and tirzepatide, the active ingredients in now-commercial drugs like Ozempic, Wegovy, Mounjaro and Zepbound, were all linked to notable levels of hair loss, and that this hair loss was strongest among those who had been using higher doses of GLP-1s to target rapid weight loss for critical health reasons. Those taking lower doses of GLP-1s for Type 2 diabetes were less likely to be affected, but hair loss was still possible, although the study’s author, Dr. Paradi Mirmirani of the University of California San Francisco added that users should generally be “not alarmed” by the findings.
“Hair shedding can occur with some GLP‑1 medications, especially with rapid weight loss — but it is usually temporary, reversible, and manageable,” said Mirmirani, speaking to SFGate. “With good counseling, steady weight loss, and attention to nutrition, most patients can continue therapy safely.”
The culprit, as one might intuit, is not necessarily the drugs themselves but likely a side effect of the intended result of the drug: lower appetite. As a result, those taking GLP-1s can end up facing issues of malnutrition, or lacking a balanced diet that means they miss out on important vitamins or minerals that support scalp health. In general, the association is pretty strong, with instances of hair loss found across 24 studies that were indexed. A separate 2025 meta-analysis, including more than 84,000 GLP-1 users across 34 studies, similarly concluded that those taking the drugs were 3.4 times more likely to experience hair loss compared to those who were not. Mirmarani said she recommended GLP-1 users minimize this risk by avoiding what she termed “prolonged severe caloric restriction,” and pursuing a balanced diet with enough protein and vitamin content. Or in other words, what might seem like common sense: You can’t just mostly stop eating when you’re taking GLP-1s! The human body still needs proper nutrition, even when you’re taking drugs to suppress appetite. Who would have thought?
Did you know that women taking GLP-1 drugs like Ozempic may face over double the hair loss risk compared to those on other treatments? A deep dive into the data reveals startling insights that could change how we view these medications. Curious?
— Digital Brain (@yourdigitalbrain.bsky.social) May 1, 2026 at 4:11 PM
The study of the effectiveness, potential health risks, large-scale benefit and long-term effects of GLP-1s is a field that will be turning out regular findings for decades to come, given the millions, and perhaps billions of people worldwide interested in weight loss for one reason or the other. We’re still only scratching the surface of the complex, multifaceted impact these drugs will have on the wider medical and mental health world, not to mention fields like the food and drink industries, who must suddenly contend with the idea of millions of people radically changing their ingrained eating and drinking habits. It’s the type of upheaval toward the treatment of food that society has rarely seen before, comparable perhaps to the way that mass-produced crystalline sugar first became commonplace in American households in the dawn of the 20th century, changing our diets forever.
What we do know is that GLP-1s have already had an undeniable effect on our population, and its mortality. Study after study has demonstrated that these drugs decrease the overall chance of death, primarily by reducing the risk of cardiovascular events like heart attack or stroke, along with managing blood sugar and reducing obesity. Other research has found GLP-1s could provide benefits for a wide variety of other conditions as well, such as kidney disease or colon cancer, thanks to its link to metabolic inflammation. The flip side of that equation is that most of these gains seem to be short lived when people stop using the medication: GLP-1s, generally speaking, really are intended to be taken for the rest of one’s life in most cases.
“There is enormous exuberance about starting GLP-1 drugs, but not nearly enough attention to what happens when people stop,” said senior author Ziyad Al-Aly, MD, a WashU Medicine clinical epidemiologist, of a study about the effects of quitting GLP-1 drugs. “Many quit after a few months because of cost, side effects or shortages. When they stop, it’s not just weight that comes back; they experience a resurgence in inflammation, blood pressure, and cholesterol. Weight regain is visible; the metabolic reversal is not.”
Which is all to say that these class of drugs remain a calculated tool that is no doubt useful for some patients, but by no means a one-size-fits-all solution, requiring careful consideration of the benefits and risks. The prospect of potentially losing your thick, luscious locks is just another factor in a decision that many millions of Americans now find themselves making.